Morgan Stanley Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $12.00

Bausch + Lomb (NYSE:BLCO - Free Report) had its price target reduced by Morgan Stanley from $18.00 to $12.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Several other research firms also recently weighed in on BLCO. Wells Fargo & Company reduced their target price on shares of Bausch + Lomb from $15.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday, May 1st. Royal Bank of Canada decreased their price objective on Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating on the stock in a research note on Friday, April 4th. Bank of America cut their target price on Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a research note on Thursday, February 20th. Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a report on Thursday, April 24th. Finally, Stifel Nicolaus reduced their price objective on shares of Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating for the company in a research note on Thursday, April 3rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $15.50.

Bausch + Lomb Stock Performance

NYSE BLCO traded down $0.11 during trading hours on Tuesday, reaching $11.39. 94,191 shares of the company were exchanged, compared to its average volume of 647,004. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $4.02 billion, a P/E ratio of -12.52, a P/E/G ratio of 0.85 and a beta of 0.58. Bausch + Lomb has a 1 year low of $10.45 and a 1 year high of $21.69. The business's 50 day simple moving average is $13.54 and its 200-day simple moving average is $16.65.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.10). Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The company had revenue of $1.15 billion during the quarter, compared to the consensus estimate of $1.15 billion. During the same period last year, the firm posted $0.07 EPS. The company's revenue for the quarter was up 3.5% compared to the same quarter last year. On average, equities research analysts expect that Bausch + Lomb will post 0.74 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BLCO. Blue Trust Inc. raised its position in Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock worth $48,000 after purchasing an additional 1,004 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of Bausch + Lomb in the 4th quarter valued at about $72,000. Commonwealth Equity Services LLC bought a new position in Bausch + Lomb during the 4th quarter worth approximately $181,000. Alpine Global Management LLC bought a new stake in Bausch + Lomb in the fourth quarter valued at approximately $181,000. Finally, Covestor Ltd bought a new position in shares of Bausch + Lomb in the fourth quarter worth approximately $188,000. 11.07% of the stock is owned by hedge funds and other institutional investors.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.